test

Developmental Therapeutics

Charles H Cha MD, FACS

Associate Professor of Surgery (Oncology and Gastrointestinal)

Research Interests

Development of robotic and laparoscopic approaches for benign and malignant conditions of the liver, pancreas and stomach; Effects of angiogenesis on gastrointestinal malignancy; Gene silencing techniques to knockdown proliferation of hepatocellular carcinoma in vitro and in vivo; Diagnostic and therapeutic utility of angiogenic inhibitors for treatment of solid tumors; Clinical outcomes in surgery for sarcoma, hepatobiliary, gastric and esophageal malignancy


Research Summary

Dr. Cha has established an active research laboratory studying the effects of angiogenesis on colorectal and liver malignancy using gene-silencing techniques to silence angiogenic factors leading to decreased tumor growth. He collaborates with a number of Yale researchers to use nanoparticle delivery systems to target tumor cells before they can grow larger than a few millimeters in size. His laboratory effort has resulted in support from a number of funding sources including the Hartford Foundation, American College of Surgeons Faculty Research Award, Ohse Foundation, and the VA Healthcare System Career Development Award. His clinical research interests include the determination of the diagnostic and therapeutic utility of angiogenic inhibitors for treatment of colorectal and liver cancers. In addition, he is involved in clinical outcomes research in surgery for liver, gastric, esophageal and colorectal malignancy using the National Surgical Quality Improvement Program Database as well as the Connecticut Tumor Registry. In his lab, Dr. Cha has mentored a number of medical students, surgical residents, fellows and postdoctoral students including Steve Ward, MD, Abby Mulkeen, MD, Peter Yoo, MD, Sharon Kiang, MD, and Wenli Gao, PhD., leading to over 20 publications and honors such as Best Resident Paper at the New England Surgical Society (Mulkeen), Ohse Foundation Award (Mulkeen, Yoo), Pfizer/ACS Travel Scholarship (Yoo), Best Case Presentation Connecticut Chapter, ACS (Yoo), NIH LRP Award (Yoo).

Extensive Research Description

Dr. Cha has established an active research laboratory studying the effects of angiogenesis on colorectal and liver malignancy using gene-silencing techniques to silence angiogenic factors leading to decreased tumor growth. He collaborates with a number of Yale researchers to use nanoparticle delivery systems to target tumor cells before they can grow larger than a few millimeters in size. His laboratory effort has resulted in support from a number of funding sources including the Hartford Foundation, American College of Surgeons Faculty Research Award, Ohse Foundation, and the VA Healthcare System Career Development Award. His clinical research interests include the determination of the diagnostic and therapeutic utility of angiogenic inhibitors for treatment of colorectal and liver cancers. In addition, he is involved in clinical outcomes research in surgery for liver, gastric, esophageal and colorectal malignancy using the National Surgical Quality Improvement Program Database as well as the Connecticut Tumor Registry. In his lab, Dr. Cha has mentored a number of medical students, surgical residents, fellows and postdoctoral students including Steve Ward, MD, Abby Mulkeen, MD, Peter Yoo, MD, Sharon Kiang, MD, and Wenli Gao, PhD., leading to over 20 publications and honors such as Best Resident Paper at the New England Surgical Society (Mulkeen), Ohse Foundation Award (Mulkeen, Yoo), Pfizer/ACS Travel Scholarship (Yoo), Best Case Presentation Connecticut Chapter, ACS (Yoo), NIH LRP Award (Yoo).


Selected Publications

  • Kiang, W., Gao, P., Yoo, J., Schmitz, E., Chu, E., Uchio, S. Kulkarni , C. Cha. HuR protein downregulation as an antitumor strategy. Journal of the American College of Surgeons, Volume 207, Issue 3, Pages S96 - S96, 2008.
  • Yoo PS, Sullivan CA, Kiang S, Gao W, Uchio EM, Chung GG, Cha CH. Tissue Microarray Analysis of 560 Patients with Colorectal Adenocarcinoma: High Expression of HuR Predicts Poor Survival. Annals of Surgical Oncology ;16(1):200-7. 2009.
  • Yeo, H, Shariff, A, Cha, C. Advances in Surgical Therapy for Esophageal Cancer. Emerging Cancer Therapeutics; 1:19-34, 2010
  • Cha CH, Saif MW, Yamane BH, Weber SM. Hepatocellular carcinoma. Curr Probl Surg. 2010 Jan;47(1):6-8.
  • Kozol RA, Hyman N, Strong S, Whelan RL, Cha C, Longo WE. Minimizing risk in colon and rectal surgery. American Journal of Surgery, 2007, Nov;194(5):576-87.
  • Yoo PS, Mulkeen A, Dardik A, Cha C. A novel in vitro model of lymphatic metastasis from colorectal cancer. Journal of Surgical Research, 2007, Nov;143(1):94-8.
  • Kuda FA, Muto A, Maloney SP, Pimiento JM, Bergaya S, Fitzgerald TN, Westvik TS, Frattini JC, Breuer CK, Cha CH, Nishibe T, Tellides G, Sessa WC, Dardik A. Venous identity is lost but arterial identity is not gained during vein graft adaptation, Arteriosclerosis, Thrombosis, and Vascular Biology, 2007 Jul;27(7):1562-71.
  • Yoo PS, Lopez-Soler RI, Longo WE, Cha CH. Liver resection for metastatic colorectal cancer in the age of neoadjuvant chemotherapy and bevacizumab. Clinical Colorectal Cancer. 2006 Sep;6(3):202-7.
  • Yoo PS, Mulkeen A, Frattini JC, Longo WE, Cha C. Assessing risk factors for adverse outcomes in emergent colorectal surgery. Surgical Oncology, 2006, Aug: 15(2):85-9.

Edit Profile